FGF23 and Iron deficiency anemia: The use of burosumab has also been reported in FGF23-mediated hypophosphatemic osteomalacia secondary to repeated intravenous iron infusions in a 32-yr-old man with severe Crohn’s disease and iron-deficiency anemia.42